Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

Its lead candidate, VK2735, will start its phase 3 clinical trials soon after the company meets with regulators at the Food and Drug Administration to discuss a few details; assuming standard ...

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...

Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...

Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 study ...

Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company ...

The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...

Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001).